Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 8/20 | 0.71 |
| ▸ | EIF4E | P06730 | 1/20 | 0.56 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.56 |
| ▸ | PRKAR2A | P13861 | 7/20 | 0.52 |
| ▸ | PRKAR2B | P31323 | 5/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24473339 | 0.95 | NTSR2 (0.73) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473505 | 0.95 | NTSR2 (0.73) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473663 | 0.91 | NTSR2 (0.61) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473539 | 0.91 | NTSR2 (0.61) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473416 | 0.87 | NTSR2 (0.60) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473637 | 0.85 | NTSR2 (0.61) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473579 | 0.84 | NTSR2 (0.53) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473488 | 0.83 | NTSR2 (1.00) | NTSR2NTSR1 | |
| SCHEMBL24473534 | 0.81 | NTSR2 (0.53) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473338 | 0.81 | NTSR2 (0.77) | NTSR2EIF4EEIF4EBP1PRKAR2APRKAR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | NTSR2 2/4885EIF4E 3054/4885EIF4EBP1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.